ANI Pharmaceuticals reported $29.49M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
ANI Pharmaceuticals USD 29.49M 2.86M Mar/2026
Aurora Cannabis CAD 1.82M 53.29M Dec/2025
Canopy Growth CAD -62.63M 60.99M Dec/2025
Eli Lilly USD 7.4B 760M Mar/2026
Emergent BioSolutions USD -261.3M 78.3M Jun/2023
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Hikma Pharmaceutical USD 164M 45M Dec/2025
Knight Therapeutics CAD -3.79M 8.83M Sep/2025
Nektar Therapeutics USD -36.08M 978K Dec/2025
Novartis USD 2.41B 1.52B Dec/2025
Omeros USD -32.23M 23.81M Sep/2024
Perrigo USD -398.6M 1.02B Mar/2026
Sun Pharmaceuticals INR 33.69B 2.51B Dec/2025
Teva Pharmaceutical Industries USD 369M 111M Mar/2026